OBJECTIVE: To compare the number and type of nevirapine (NVP) resistance mutations detected in Ugandan women with subtype A vs. D HIV-1 infection after single-dose NVP prophylaxis. DESIGN: In the HIVNET 012 trial, a higher rate of NVP resistance (NVPR) was seen in women with subtype D than A after single-dose NVP. In this study, the number and type of NVPR mutations detected 6-8 weeks after NVP were compared in women with subtypes A vs. D. METHODS: Plasma samples were available for 282 (92%) of 306 women who received NVP in HIVNET 012. Samples were analyzed with the ViroSeq HIV-1 Genotyping System (Applied Biosystems, Foster City, CA). Subtyping was performed by phylogenetic analysis of pol region sequences. RESULTS: Results were obtained for 279 women, including 147 with subtype A, 98 with subtype D, 6 with subtype C, and 28 with recombinant HIV-1. NVPR mutations were detected in 70 (25%) of 279 women. NVPR was more common in women with subtype D vs. A (35.7 vs. 19%, P = 0.0035). Complex patterns of NVPR mutations were detected in both subtypes. Among women with NVPR, 43% of women with subtype A and 46% of women with subtype D had >/=2 NVPR mutations. The mean number and pattern of NVPR mutations detected in women with subtypes A and D were similar. CONCLUSIONS: This study confirms a higher rate of NVPR in women with subtype D than A and further defines the pattern of NVPR mutations that emerge 6-8 weeks after single-dose NVP prophylaxis in these subtypes.
OBJECTIVE: To compare the number and type of nevirapine (NVP) resistance mutations detected in Ugandan women with subtype A vs. D HIV-1 infection after single-dose NVP prophylaxis. DESIGN: In the HIVNET 012 trial, a higher rate of NVP resistance (NVPR) was seen in women with subtype D than A after single-dose NVP. In this study, the number and type of NVPR mutations detected 6-8 weeks after NVP were compared in women with subtypes A vs. D. METHODS: Plasma samples were available for 282 (92%) of 306 women who received NVP in HIVNET 012. Samples were analyzed with the ViroSeq HIV-1 Genotyping System (Applied Biosystems, Foster City, CA). Subtyping was performed by phylogenetic analysis of pol region sequences. RESULTS: Results were obtained for 279 women, including 147 with subtype A, 98 with subtype D, 6 with subtype C, and 28 with recombinant HIV-1. NVPR mutations were detected in 70 (25%) of 279 women. NVPR was more common in women with subtype D vs. A (35.7 vs. 19%, P = 0.0035). Complex patterns of NVPR mutations were detected in both subtypes. Among women with NVPR, 43% of women with subtype A and 46% of women with subtype D had >/=2 NVPR mutations. The mean number and pattern of NVPR mutations detected in women with subtypes A and D were similar. CONCLUSIONS: This study confirms a higher rate of NVPR in women with subtype D than A and further defines the pattern of NVPR mutations that emerge 6-8 weeks after single-dose NVP prophylaxis in these subtypes.
Authors: William I Towler; Linda Barlow-Mosha; Jessica D Church; Danstan Bagenda; Patrick Ajuna; Micheal Mubiru; Philippa Musoke; Susan H Eshleman Journal: AIDS Res Hum Retroviruses Date: 2010-05 Impact factor: 2.205
Authors: Russell B Van Dyke; Nicole Ngo-Giang-Huong; David E Shapiro; Lisa Frenkel; Paula Britto; Anuvat Roongpisuthipong; Ingrid A Beck; Praparb Yuthavisuthi; Sinart Prommas; Thanyawee Puthanakit; Jullapong Achalapong; Nantasak Chotivanich; Wirawan Rasri; Tim R Cressey; Robert Maupin; Mark Mirochnick; Gonzague Jourdain Journal: Clin Infect Dis Date: 2011-12-05 Impact factor: 9.079
Authors: Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex Journal: J Clin Microbiol Date: 2015-06-03 Impact factor: 5.948
Authors: Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman Journal: J Int AIDS Soc Date: 2010-02-03 Impact factor: 5.396
Authors: David W Haas; Tebeb Gebretsadik; Gail Mayo; Usha N Menon; Edward P Acosta; Ayumi Shintani; Michael Floyd; C Michael Stein; Grant R Wilkinson Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: Jessica M Fogel; Anthony Mwatha; Paul Richardson; Elizabeth R Brown; Tsungai Chipato; Michel Alexandre; Dhayendre Moodley; Ali Elbireer; Mark Mirochnick; Kathleen George; Lynne M Mofenson; Sheryl Zwerski; Hoosen M Coovadia; Susan H Eshleman Journal: Pediatr Infect Dis J Date: 2013-04 Impact factor: 2.129
Authors: Sarah E Hudelson; Michelle S McConnell; Danstan Bagenda; Estelle Piwowar-Manning; Teresa L Parsons; Monica L Nolan; Paul M Bakaki; Michael C Thigpen; Michael Mubiru; Mary Glenn Fowler; Susan H Eshleman Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Oliver Laeyendecker; Jessica D Church; Amy E Oliver; Anthony Mwatha; S Michele Owen; Deborah Donnell; Ron Brookmeyer; Philippa Musoke; J Brooks Jackson; Laura Guay; Clemesia Nakabiito; Thomas C Quinn; Susan H Eshleman Journal: PLoS One Date: 2010-10-11 Impact factor: 3.240